Loading
Life sciences · Journal article
Cell Communication and Signaling · September 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Breast cancer continues to be the second leading cause of cancer-related deaths among women worldwide. The heterogeneity of this disease poses a major challenge to clinical treatment. Recent advancements in molecular biology and immunology have enabled the development of highly targeted therapies for various breast cancer subtypes. A variety of immunotherapies, including immune-checkpoint blockade, cancer vaccination, and tumor microenvironment regulation, have been extensively investigated in breast cancer. The central aim of targeted therapy is to inhibit specific molecules which drive the progression of breast cancer. Despite the great progress in current clinical diagnosis and treatment, innate and acquired drug resistance still significantly limit the duration of efficacy of targeted and immunotherapy. As a class of regulatory transcripts with diverse functions, non-coding RNAs(ncRNAs) are involved in the regulation of multiple oncogenic signal axes and pathological processes. A large number of studies have confirmed that ncRNAs can mediate breast cancer drug resistance through multiple mechanisms such as regulating core signaling pathways, tumor cell proliferation and apoptosis, epigenetic modification, tumor microenvironment homeostasis, and drug metabolism. This review systematically summarizes the multiple regulatory effects of ncRNAs in breast cancer targeted therapy and immunotherapy resistance, and analyzes the research status, existing shortcomings and clinical transformation potential of ncRNA-related therapeutic methods, in order to provide a new research perspective for solving the clinical drug resistance problem and promote the development of ncRNA-targeted combined intervention strategies for breast cancer.